Ibrutinib US FDA Label

  • Compound: 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
  • Description: Ibrutinib is a member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies. It has a role as an EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor and an antineoplastic agent. It is a pyrazolopyrimidine, an aromatic amine, an aromatic ether, a member of acrylamides, a N-acylpiperidine and a tertiary carboxamide.

Identifiers (5)

  • International Nonproprietary Name: IBRUTINIB [INN] (Source: PubChem)
  • KEGG Drug ID: D10223 (Source: PubChem)
  • SureChEMBL ID: SCHEMBL201859 (Source: PubChem)
  • USFDA Precision ID: UNII-1X70OSD4VX (Source: PubChem)
  • US Adopted Name: Ibrutinib [USAN] (Source: PubChem)